Table 2.

KEGG pathway enrichment analysis of Que against AF.

Pathway	Enrichment	P value	Symbols	Count
AGE-RAGE signaling pathway in diabetic complications	29.23	7.01E − 22	NOX4, VEGFA, CCND1, BAX, JUN, IL-6, PRKCA, STAT1, IL-1B, SELE, CSCL8, TGFB1, THBD, SERPINE, COLA1A, COL3A1, JAK2, MAPK14, CD42	19
Lipid and atherosclerosis	35.38	1.45E − 20	PTK2, MMP9, CAMK2B, PPARG, FOS, BAX, JUN, IL6, NFKBIA, PRKCA, IL1B, SELE, CXCL8, NFE2L2, CXCL2, CASP1, JAK2, MAPK14, HSP90AA1, CCL5, RHOA, CDC42, HSPA42	23
Fluid shear stress and atherosclerosis	23.08	1.51E − 13	PTK2, MMP9, VEGFA, FOS, JUN, IL1B, SELE, THBD, NFE2L2, NQ01, MAPK14, HSP90AA1, RHOA, GSTO1, ACTB	15
Proteoglycans in cancer	26.15	2.33E − 13	PTK2, MMP9, CAMK2B, VEGFA, CND1, PRKCA, MYC, TGFB1, COL1A1, FGFR1, ESR1, PRKACA, MAPK14, RHOA, CDC42, ACTB	17
Human cytomegalovirus infection	24.61	1.41E − 11	PTK2, PTGS2, VEGFA, CCND1, BAX, IL6, NFKBIA, PRKCA, MYC, IL1B, CXCL8, PRKACA, MAPK14, CCL5, RHOA	16
Kaposi sarcoma-associated herpesvirus infection	21.54	2.64E − 10	VEGFA, CCND1, FOS, BAX, JUN, IL6, NFKBIA, STAT1, MYC, CXCL8, CXCL2, JAK2, MAPK14	14
Hepatitis B	20.00	3.34E − 10	FOS, BAX, JUN, IL6, NFKBIA, PRKCA, STAT1, MYC, CXCL8, TGFB1, JAK2, MAPK14	13
MAPK signaling pathway	24.62	7.75E − 10	MAPT, INSR, VEGFA, FOS, JUN, PRKCA, MYC, IL1B, HSPB1, TGFB1, FGFR1, PRKACA, MAPK14, CDC42, HSPA2	16
Salmonella infection	21.54	6.95E − 09	BAX, JUN, IL6, NFKBIA, MYC, IL1B, CXCL8, CASP1, MAPK14, HSP90AA1, RHOA, CDC42, ACTB	14
Chemical carcinogenesis—receptor activation	20.00	9.16E − 09	VEGFA, CCND1, FOS, JUN, PRKCA, MYC, PPARA, JAK2, ESR1, PRKACA, HSP90AA1, GSTO1	13